免疫抑制剂对新型隐球菌的体外活性。
In vitro activity of immunosuppressive agents against Cryptococcus neoformans.
作者信息
Rossato Luana, Venturini Tarcieli P, de Azevedo Maria Isabel, Santurio Janio M, Alves Sydney H
机构信息
Postgraduate Program in Pharmaceutical Sciences, Health Sciences Centre, Federal University of Santa Maria (UFSM), Santa Maria, RS, Brazil.
Postgraduate Program in Pharmaceutical Sciences, Health Sciences Centre, Federal University of Santa Maria (UFSM), Santa Maria, RS, Brazil.
出版信息
Enferm Infecc Microbiol Clin (Engl Ed). 2022 Feb;40(2):86-88. doi: 10.1016/j.eimce.2020.09.007.
INTRODUCTION
Infections caused by Cryptococcus neoformans are a major cause of fungal mortality in HIV-infected/AIDS patients and in those receiving organ transplants. We evaluated the in vitro activity of tacrolimus and cyclosporine in combination with amphotericin B and fluconazole against C. neoformans.
METHODS
MICs were determined against a total of 30 clinical isolates of C. neoformans by the microdilution method following the CLSI M27-A3 guidelines and by the checkerboard method.
RESULTS
Tacrolimus and cyclosporine A showed in vitro activity against cryptococcal isolates. The combination of amphotericin B with cyclosporine A or tacrolimus was synergistic against 90% and 30% of isolates, respectively. Synergism was also observed with the combination of fluconazole with cyclosporine A or tacrolimus, against 70% and 20% of isolates, respectively.
CONCLUSIONS
The synergistic interactions between the calcineurin inhibitors and antifungal drugs against C. neoformans isolates, could potentially have a role in devising novel therapeutic strategies for this opportunistic mycosis.
引言
新型隐球菌引起的感染是艾滋病毒感染/艾滋病患者以及接受器官移植者真菌致死的主要原因。我们评估了他克莫司和环孢素与两性霉素B和氟康唑联合使用对新型隐球菌的体外活性。
方法
按照CLSI M27 - A3指南，采用微量稀释法和棋盘法对总共30株新型隐球菌临床分离株测定最低抑菌浓度（MIC）。
结果
他克莫司和环孢素A对隐球菌分离株显示出体外活性。两性霉素B与环孢素A或他克莫司联合使用时，分别对90%和30%的分离株具有协同作用。氟康唑与环孢素A或他克莫司联合使用时，也分别对70%和20%的分离株观察到协同作用。
结论
钙调神经磷酸酶抑制剂与抗真菌药物对新型隐球菌分离株之间的协同相互作用，可能在为这种机会性真菌病设计新的治疗策略中发挥作用。
Zotero 插件